[Alloy Therapeutics in BusinessWire] Alloy Therapeutics announces a target specific collaboration and license agreement for use of AntiClastic™ Antisense Platform with Sanofi
BOSTON–(BUSINESS WIRE)–Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug discovery technologies, announced today a target specific collaboration and license agreement for the use of their novel and proprietary AntiClastic Antisense Platform with Sanofi for a central nervous system (CNS) target. Read...
Read More